Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

106.49

+1.14 (1.08%)

At close: Aug 31, 2026, 4:00 PM EDT

106.50

+0.01 (0.01%)

After-hours: Aug 31, 2026, 7:58 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Quarter	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Mar '24 Mar 31, 2024	Dec '23 Dec 31, 2023	Sep '23 Sep 30, 2023	Jun '23 Jun 30, 2023	Mar '23 Mar 31, 2023	Dec '22 Dec 31, 2022	Sep '22 Sep 30, 2022	Jun '22 Jun 30, 2022	Mar '22 Mar 31, 2022	Dec '21 Dec 31, 2021	Sep '21 Sep 30, 2021	Jun '21 Jun 30, 2021	Mar '21 Mar 31, 2021	Dec '20 Dec 31, 2020	Sep '20 Sep 30, 2020
Royalties Revenue	307.70M
Sales of Proprietary Products	55.43M
Sales of Bulk rHuPH20	59.62M
Sales of Device Partnered Products	14.58M
Total Net Product Sales	129.63M
Revenue Under Collaborative Agreements	43.67M
Revenue (Total)	481.00M